In support of this view, Ruiz et al. (2017) documented that tacrolimus rescued gene expression dysregulations associated with ALK1 inhibition by increasing the ALK1 signalling pathway in endothelial cells derived from HHT patients. The gene discussed is ACVRL1; the disease is hereditary hemorrhagic telangiectasia.